The new medication was one of two aflibercept biosimilars approved by the US Food and Drug Administration in May.

which it’s developing for wet age-related macular degeneration and diabetic macular edema. The results it unveiled Wednesday ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

A: Fundus showing mild clinically significant macular edema in a young patient without cataract. B: Fundus of an older patient with some lens opacification and significant macular edema ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Merck & Co. has launched a late-stage study of Restoret, the key asset in its recent $1.3 billion acquisition of eye-drug company EyeBio. Merck on Wednesday said the Phase 2b/3 study will evaluate ...

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

Rahway: Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Bayer to present new analyses from pivotal trials PULSAR & PHOTON featuring Eylea 8 mg at EURETINA: Berlin Thursday, September 12, 2024, 17:00 Hrs [IST] Bayer will present new ana ...

Roche, represented by Ali Abdulwahab Al Mutawa Commercial Company (AAW) in Kuwait, announced today that the European ...

About diabetic macular edema Diabetic macular edema (DME) is a serious retinal condition that poses a risk to vision, potentially leading to blindness and a reduced quality of life if left untreated.